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Vein graft neointimal hyperplasia is exacerbated by
CXCR4 signaling in vein graft-extrinsic cells
Lisheng Zhang, MD,a Leigh Brian, MS,a and Neil J. Freedman, MD,a,b Durham, NC
Objective: Because vein graft neointimal hyperplasia engenders vein graft failure, and because most vein graft neointimal
cells derive from outside the vein graft, we sought to determine whether vein graft neointimal hyperplasia is affected by
activity of the CXC chemokine receptor-4 (CXCR4), which is important for bone marrow-derived cell migration.
Methods: In congenic Cxcr4/ and wild-type (WT) recipient mice, we performed interposition grafting of the common
carotid artery with the inferior vena cava (IVC) of either Cxcr4/ or WT mice to create four surgically chimeric groups
of mice (n > 5 each), characterized by vein graft donor/recipient: WT/WT; Cxcr4//WT; WT/Cxcr4/; and
Cxcr4//Cxcr4/; vein grafts were harvested 6 weeks postoperatively.
Results: The agonist for CXCR4 is expressed by cells in the arterializing vein graft. Vein graft neointimal hyperplasia was
reduced by reducing CXCR4 activity in vein graft-extrinsic cells, but not in vein graft-intrinsic cells: the rank order of
neointimal hyperplasia was WT/WT  Cxcr4//WT > WT/Cxcr4/  Cxcr4//Cxcr4/; CXCR4 deficiency in
graft-extrinsic cells reduced neointimal hyperplasia by 39% to 47% (P< .05). Vein graft medial area was equivalent in all
grafts except Cxcr4//Cxcr4/, in which the medial area was 60%  20% greater (P < .05). Vein graft re-
endothelialization was indistinguishable among all three vein graft groups. However, the prevalence of medial leukocytes
was 40% 10% lower inCxcr4//Cxcr4/ than inWT/WT vein grafts (P< .05), and the prevalence of smoothmuscle
actin-positive cells was 45%  20% higher (P < .05).
Conclusions: We conclude that CXCR4 contributes to vein graft neointimal hyperplasia through mechanisms that alter
homing to the vein graft of graft-extrinsic cells, particularly leukocytes. ( J Vasc Surg 2012;56:1390-7.)
Clinical Relevance: The utility of autologous vein grafts is severely reduced by neointimal hyperplasia, which accelerates
subsequent graft atherosclerosis. Our study demonstrates that vein graft neointimal hyperplasia is aggravated by activity
of the cell-surface “CXC” chemokine receptor-4 (CXCR4), which is critical for recruitment of bone marrow-derived cells
to sites of inflammation. Our model for CXCR4 deficiency used mice with heterozygous deficiency of Cxcr4. Conse-
quently, our results suggest the possibility that a CXCR4 antagonist—like plerixafor, currently in clinical use—could be
applied to vein grafts periadventitially, and perhaps achieve beneficial effects on vein graft neointimal hyperplasia.
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qAlthough saphenous vein grafts remain the most com-
monly used conduit for arterial bypass surgery,1 their du-
rability remains suboptimal: 28% fail within 1 year of
surgery2 and 75% are either occluded or atherosclerotic
within 10 years of surgery.1 A major contributor to vein
graft failure is neointimal hyperplasia, a process in which
medial smooth muscle cells (SMCs) and vascular progeni-
tor cells proliferate and migrate into the layer subjacent to
the endothelium.3,4 Even when it does not compromise
vein graft patency, vein graft neointimal hyperplasia seems
to accelerate vein graft atherosclerosis.5
We have found that most vein graft neointimal cells
derive from cells that reside outside of the vein graft at the
time of its implantation, or from “graft-extrinsic” cells.4
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1390oreover, many of these graft-extrinsic cells derive from
he bone marrow compartment.4 Because an arterializing
ein graft constitutes an injured vessel,3 the pathogenesis of
ein graft disease involves mechanisms pertinent to tissue
epair, such as recruitment of bone marrow-derived cells.
n important cell signaling system in this process is that
omprising the chemokine known as stromal cell-derived
actor-1 (SDF-1, or CXC chemokine ligand-12 [CXCL12]),
nd its primary chemokine receptor known as CXCR4.6,7 The
DF-1/CXCR4 signaling system is critical for normal vas-
ular development8 and mediates cell-specific effects that
ngender distinct inflammatory phenotypes (Fig 1). For
xample, CXCR4 promotes migration of both bone
arrow-derived cells9 and SMCs.10,11 However, whereas
XCR4 signaling reduces proliferation of hematopoietic
tem cells12 and induces endothelial cell apoptosis,13 it
eems to promote proliferation of SMCs.11 In vivo,
XCR4 activation contributes to neointimal hyperplasia
ssociated with wire-mediated arterial injury.14,15 None-
heless, CXCR4 activation seems to protect against athero-
clerosis by reducing atherosclerotic plaque infiltration by
eutrophils.16 How the SDF-1/CXCR4 signaling system
ffects inflammation in the arterializing vein graft and conse-
uent neointimal hyperplasia remains unknown.
This study tests the hypothesis that CXCR4 activity,
articularly in vein graft-extrinsic cells, contributes to vein
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Volume 56, Number 5 Zhang et al 1391graft neointimal hyperplasia. To do so, this study used a
mouse vein graft model that mimics human vein graft
disease,17 in that nonocclusive, SMC-rich neointimal hy-
perplasia develops over 4 to 6 weeks. Moreover, in this
model, vein graft neointimal hyperplasia is sensitive to
effects of single-gene deletions in either the vein graft
donor or the congenic vein graft recipient.18,19
METHODS
Studies of immature vein grafts. To investigate the
role of CXCR4 in the recruitment of bone marrow-derived
progenitor cells to vein graft lesions, we first evaluated
whether its ligand SDF-1 is expressed in cells constituting
the arterializing vein graft. For this purpose, we harvested
carotid interposition vein grafts from wild-type (WT) mice
2 weeks postoperatively, when the vein graft wall remains
incompletely arterialized (wall thickness and neointimal
hyperplasia reach steady state by 4 weeks postopera-
tively).17 We compared immature (2-week-old) vein grafts
with ungrafted inferior vena cava (IVC) veins from con-
genic mice (see “Histology”). In addition, we compared
vein grafts (n  4/group) implanted into WT and
Cxcr4/ recipients.
Study design for CXCR4 experiments. To study the
effects of CXCR4 physiology on vein graft disease, we used
CXCR4-deficient and congenic WT, C57BL/6 mice.
However, because CXCR4 deficiency is lethal in the em-
bryonic or perinatal period,8 we usedCxcr4/mice as our
model for CXCR4 loss of function. We implanted interpo-
sition vein grafts from WT and congenic Cxcr4/ mice
into the common carotid arteries of WT orCxcr4/mice,
and thereby created four groups of vein graft donor/
recipient mice: WT/WT,Cxcr4//WT, WT/Cxcr4/,
and Cxcr4//Cxcr4/. With these four groups, we
could test whether neointimal hyperplasia is reduced by
CXCR4 loss of function (heterozygosity) in vein graft-
intrinsic cells, vein graft-extrinsic cells, or both cell types.
Vein grafts were harvested 6 weeks postoperatively, after
neointimal hyperplasia in WT grafts reaches steady state.17
Mice. WT and congenic Cxcr4/ mice on the
Fig 1. Possible roles of the stromal-derived factor-1 (SD
in vein graft neointimal hyperplasia. Green arrows (with
inhibition, or reduction. PMN, Polymorphonuclear neuC57BL/6 genetic background were purchased from Jack- ton Laboratories (Bar Harbor, Me), and maintained as we
eported.17 All animal experiments were performed accord-
ng to protocols approved by the Duke University Institu-
ional Animal Care and Use Committee and complied with
he Guide for the Care and Use of Laboratory Animals
National Research Council).
Vein graft surgery. Interposition vein graft surgery
as performed as described previously.17-19 IVCs from WT
r congenic Cxcr4/ donor mice were anastomosed end-
o-side to the right common carotid artery of WT or
ongenic Cxcr4/ recipient mice. After both vein graft
nastomoses were secured, the intervening common ca-
otid artery was ligated and cut. All vein graft donors and
ecipients were matched for gender and age (10-15 weeks
ld), and there were at least five independent vein graft
onors/recipients for each genotypic group. All four sur-
ical groups underwent surgery contemporaneously, and
he surgeon was blinded to the genotype of the mice. At 2
r 6 weeks postoperatively, mice were euthanized and vein
rafts were harvested as described,17,18 with phosphate-
uffered saline (PBS) perfusion to achieve exsanguination
ollowed by perfusion fixation with PBS/formalin (para-
fin-embedded specimens) or incubation in 30% sucrose/
BS overnight followed by embedding in optimal cutting
emperature compound (frozen sections).
Histology. All specimens were sectioned at 5 m,
rom the distal or middle third of the vein graft specimens;
ll four vein graft groups were matched for section location,
o as to minimize variation among grafts of identical
onor/recipient genotype groups.17 WT vein grafts im-
lanted into WT recipient mice (“WT/WT”) developed neo-
ntimal hyperplasia characteristic of the pre-atherosclerotic
tages of human vein graft disease17: multiple layers of SMCs
hat do not cause significant luminal stenosis.
Morphometry was performed as described,17 on
erfusion-fixed specimens stained with a modified Mas-
on trichrome and Verhoeff elastic tissue stain that facili-
ates the simultaneous identification of collagen (green), elas-
in (black), cytoplasm (red), and nuclei (black).17 The
eointimal/medial boundary was defined as the transi-
CXC chemokine receptor-4 (CXCR4) signaling system
) indicate augmentation; red lines (with “”) indicate
il; SMC, smooth muscle cell.F-1)/
“”ion from the cytoplasm-rich, disorganized neointima to
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November 20121392 Zhang et althe collagen-rich media.17 The medial/adventitial
boundary was defined as the transition from the more
densely organized medial collagen to the less densely
organized, vasa vasorum-containing collagenous net-
work of the adventitia.17 The neointimal area was mea-
sured as the cross-sectional area subtended by the lumi-
nal perimeter and the neointimal/medial boundary. The
medial area was measured as the cross-sectional area subten-
ded by the neointimal/medial and medial/adventitial bound-
aries. All measurements were made on two sections per vein
graft, by observers blinded to specimen identity.
We stained immunofluorescently as described,4,18,20
with the following immunoglobulin Gs (IgGs; or corre-
sponding isotype negative-control IgGs): rabbit anti-
SDF-1 (Santa Cruz Biotechnology, Santa Cruz, Calif),
mouse anti-collagen I (Sigma-Aldrich, St. Louis, Mo), and
anti-SMC--actin (Cy5-conjugated 1A4; Sigma-Aldrich)
and rabbit anti-CD45 (H-230, Santa Cruz Biotechnol-
ogy), for the purpose of recognizing fibrocytes21 as well as
leukocytes. Immunofluorescence microscopy with narrow
band-pass filters was performed as described.4,18,19,22 Pro-
tein immunofluorescence was normalized to DNA fluores-
cence in the same microscopic field, and quantitated as
described.4,18-20,22,23 Morphometric and immunofluores-
cence data were quantitated by observers blinded to speci-
Fig 2. Stromal-derived factor-1 (SDF-1) is expressed in
wild-type (WT) mice were created with syngeneic inferio
before the completion of arterialization. IVCs from WT
Serial frozen sections were stained with SDF-1-specific
IgG/Alexa-488 (green), and Hoechst 33342 to visuali
representative of four independent vein grafts and IVC sp
The lumen is indicated by an asterisk. Equivalent results w
(Cxcr4)/, and Cxcr4//Cxcr4/ vein grafts.men identity. tVein graft endothelialization. Work from our group19
nd others24 has shown that during the early phase of
rterialization, there is significant damage to the vein graft
ndothelium. To quantitate re-endothelialization, we
tained vein graft cross-sections for von Willebrand factor
vWF), as described19; an observer blinded to specimen
dentity assessed the percentage of the luminal surface that
tained positive for vWF.19
Statistical analysis. One-way analysis of variance with
ukey’s post-hoc test for multiple comparisons was used to
nalyze morphometric and protein expression data. Data
re presented as means  SD in the text and  SE in the
gures.
ESULTS
Immature vein grafts express SDF-1. In our mouse
odel of vein grafting, immature,17 arterializing vein grafts
xpress SDF-1 protein, discerned by immunofluorescence
icroscopy of 2-week-old vein grafts (Fig 2). However, no
DF-1 could be detected in cognate IVCs that had not
een subjected to vein grafting (Fig 2). Thus, like athero-
clerotic25 and mechanically injured arteries,26 vein grafts
ay use SDF-1 to recruit cells.
CXCR4 promotes vein graft neointimal hyper-
lasia. Compared with the WT/WT control vein grafts,
rializing vein grafts. Carotid interposition vein grafts in
ae cavae (IVCs) and harvested 2 weeks postoperatively,
of equivalent age were also harvested, for comparison.
nimmune rabbit immunoglobulin G (IgG), anti-rabbit
NA (blue). Shown are sections from single specimens,
ens. Scale bar 100 m (original magnification	220).
tained with WT/WT, WT/CXC chemokine receptor-4arte
r ven
mice
or no
ze D
ecim
ere obhe Cxcr4//WT vein grafts demonstrated equivalent
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Volume 56, Number 5 Zhang et al 1393Fig 3. CXC chemokine receptor-4 (CXCR4) activity in vein
graft-extrinsic cells contributes to vein graft neointimal hyperpla-
sia. Carotid interposition vein grafts from the indicated mouse
donors were placed into the indicated congenic recipient mice and
harvested 6 weeks later, after perfusion fixation. Vein graft sections
were stained with a modified connective tissue stain. A, Photomi-
crographs of single specimens, representative of 5 obtained of
each type. Specimens are aligned at the neointimal/medial border;
the medial/adventitial borders are indicated by the arrows and
corresponding dashed lines. Scale bar  50 m (original magnifi-
cation 	440). B, Neointimal and medial areas were measured for
each specimen cross-section by an observer blinded to specimen
identity, using computerized planimetry. Total Wall refers to the
sum of neointimal plus medial areas. Shown are means  SE from
5 independent vein graft specimens from each group. Compared
with wild-type (WT)/WT control vein grafts: *P 
 .05. r
dig 4. CXC chemokine receptor-4 (CXCR4) does not affect vein
raft re-endothelialization. Vein grafts of the indicated donor/recip-
ent combinations were harvested 6 weeks postoperatively and fixed in
ormalin.A, Specimen cross-sections were fluorescently stained simul-
aneously for von Willebrand factor (vWF) to identify endothelial cells
green) and for DNA (blue). Shown are photomicrographs from
ingle samples, representative of 5 vein grafts in each group.
cale bar  100 m (original magnification 	440, lumen oriented
pward).B, The length of luminal border staining positively for vWF
as divided by the total lumen perimeter to obtain the % of graft
e-endothelialization, which is plotted as mean SE of5 indepen-
ent vein graft specimens from each group. WT, Wild-type.
t
v
s
g
n
n
w
C
I
.


(
g
n
c
n
B
v
c
m
c
v
g
6
2
w
t
w
a
d
p
l
t
4
F
g
g
m
m
c
a
c
w
a
d
S
	
1
g
n
m
e
y
i
JOURNAL OF VASCULAR SURGERY
November 20121394 Zhang et alneointimal hyperplasia, as assessed by neointimal area
(120  20 	 103 m2 vs 120  10 	 103 m2, Fig 3).
Thus, CXCR4 activity in vein graft-intrinsic cells did not
seem to affect vein graft neointimal hyperplasia. In contrastwo these vein graft findings in WT recipient mice, however,
ein grafts implanted intoCxcr4/ recipient mice showed
ubstantially less neointimal hyperplasia, whether the vein
raft donor was WT or Cxcr4/ (Fig 3). Compared with
eointimal area in WT/WT or Cxcr4//WT vein grafts,
eointimal area was 39% to 47% less in vein grafts that
ere WT/Cxcr4/ (76  9 	 103 m2) or Cxcr4//
xcr4/ (70  20 	 103 m2; P 
 .05; Fig 3, B).
ntriguingly, the medial area was 60%  20% greater (P 

05) in Cxcr4//Cxcr4/ vein grafts (320  40 	 103
m2) than in WT/WT control vein grafts (200 40	 103
m2; Fig 3). Consequently, the total vein graft wall area
media plus neointima) did not differ among the four vein
raft groups (Fig 3), and neither did the luminal area (data
ot shown). Thus, unlike CXCR4 activity in graft-intrinsic
ells, CXCR4 activity in vein graft-extrinsic cells promotes
eointimal hyperplasia.
CXCR4 does not affect vein graft re-endothelialization.
ecause the mature vein graft endothelium comprises both
ein graft-intrinsic and graft-extrinsic endothelial cells4 that
an be affected by CXCR4 activity,13 we sought to deter-
ine whether CXCR4 in graft-intrinsic or graft-extrinsic
ells affected vein graft re-endothelialization. In mature
ein grafts, the degree of endothelialization was indistin-
uishable among our four vein graft groups: WT/WT (93%
%), Cxcr4//WT (92%  7%), WT/Cxcr4/ (94% 
%) and Cxcr4//Cxcr4/ (91%  4%; Fig 4). Thus, as
ith arterial injury,15 in vein graft arterialization there seems
o be no effect of CXCR4 on re-endothelialization.
CXCR4 alters vein graft composition. To determine
hether CXCR4 in vein graft-intrinsic or graft-extrinsic cells
ltered the cellular composition of the vein graft, we first
etermined the vein graft prevalence of -SMC actin-
ositive cells. Whereas SMCs were more abundant in the
arger neointimas of WT/WT vein grafts (Figs 3 and 5),
hey were 1.6  0.2-fold more prevalent in the media of
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ig 5. CXC chemokine receptor-4 (CXCR4) activity affects vein
raft composition. Vein grafts of the indicated donor/recipient
roups were harvested 6 weeks postoperatively and stained with a
odified connective tissue stain (“Masson”), from which neointimal/
edial boundaries were identified. Serial sections were fluores-
ently stained simultaneously for -smooth muscle cell (SMC)
ctin (red) and DNA (blue) (A, middle and bottom panels), or for
ollagen type I (red) and DNA (blue) (B, upper panel). Dotted
hite lines indicate the neointimal/medial boundaries. A, SMC-
ctin-stained sections. In the middle panels, the dotted rectangles
elimit the areas further enlarged for depiction in the lower panels.
cale bars 100 m (original magnification	110, middle panels;
440, lower panels). B, Collagen I-stained sections; scale bar 
00 m (original magnification 	440). C, SMC actin and colla-
en type I fluorescence in the medial layer of each vein graft were
ormalized to cognate DNA fluorescence intensity within each
icroscopic field. The resulting ratios were normalized, within
ach staining group, to those of wild-type (WT)/WT samples to
ield % of control. Data are plotted as the means  SE of 4
ndependent vein graft specimens from each group. Compared
ith WT/WT control vein grafts: *P 
 .05.
v
D
v
m
F
o
e
b
p
C
5
r
f
a
r
D
o
s
c
n
g
g
m
C
w
m
t
e
t
c
C
t
e
l
t
v
m
s
4
F
g
V
w
s
D
S
o
2
l
c
s
%
g
c
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 5 Zhang et al 1395ein grafts from Cxcr4/ recipients (P 
 .05; Fig 5).
espite the higher prevalence of medial SMCs, however,
ein grafts from Cxcr4/ recipients had only 55% 8% as
uch medial collagen I as WT/WT vein grafts (P 
 .05;
ig 5). Nevertheless, congruently with a higher prevalence
f SMCs, the media of vein grafts from Cxcr4/ recipi-
nts had a lower prevalence of leukocytes, as demonstrated
y staining for the pan-leukocyte marker CD45: as com-
ared with WT/WT or Cxcr4//WT vein grafts, WT/
xcr4/ and Cxcr4//Cxcr4/ vein grafts had
6%  5% and 55%  6% as many medial leukocytes,
espectively (P
 .05; Fig 6). Thus, the media of vein grafts
rom Cxcr4/ recipients seems to be enriched in SMCs
nd poor in leukocytes, compared with vein grafts from WT
ecipients.
ISCUSSION
Using a genetic approach to reduce CXCR4 activity,
ur work demonstrates that vein graft neointimal hyperpla-
ia is exacerbated by CXCR4 activity in vein graft-extrinsic
ells. Our work also suggests that an SDF-1/CXCR4 sig-
aling system promotes inflammation associated with vein
raft arterialization, by demonstrating that Cxcr4/ vein
raft recipients have fewer leukocytes in the vein graft
edia. In vein grafts, the beneficial effects attributable to
XCR4 deficiency were observed when CXCR4 expression
as reduced by only 50%27 in Cxcr4/ graft recipient
ice. Consequently, these studies highlight the possibility
hat inhibiting CXCR4, at least in the local vein graft
nvironment, could achieve clinically beneficial effects.
The importance of the SDF-1/CXCR4 signaling sys-
em in vein graft arterialization accords with current con-
epts regarding the pathophysiology of vein graft disease.
onsequent to the barotrauma associated with implanta-
ion in the arterial circuit,3,24,28 defects in the vein graft
ndothelium trigger platelet adhesion to the vein graft’s
uminal surface; platelet-secreted SDF-129 then functions
o recruit vein graft-extrinsic cells to the vein graft. During
ein graft arterialization, cells of the burgeoning vein graft
edia and neointima also secrete SDF-1, as Fig 2 demon-
trates. Reducing CXCR4 activity in both vein graft-
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ig 6. CXC chemokine receptor-4 (CXCR4) activity in vein
raft-extrinsic cells promotes leukocyte recruitment to vein grafts.
ein grafts with donors and recipients of the indicated genotypes
ere harvested 6 weeks postoperatively and were fluorescently
tained simultaneously for CD45 (green) and DNA (blue). A,
otted white lines indicate the neointimal/medial boundaries.
hown are photomicrographs from single samples, representative
f4 in each group. Scale bar 100 m (original magnification	
20, lumen oriented upward). B, CD45 fluorescence in the medial
ayer of each vein graft was normalized to cognate DNA fluores-
ence intensity; the resulting ratios were normalized within each
taining group to those of wild-type (WT)/WT samples to yield
of control, plotted as the means  SE of 4 independent vein
raft specimens from each group. Compared with WT/WT
ontrol vein grafts: *P 
 .05.
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perplasia substantially. However, inhibiting CXCR4 activ-
ity globally does not seem to engender thinning of the vein
graft wall overall because of increased medial hypertrophy
(Fig 3). Thus, because they may not prevent medial or total
vein graft wall thickening, vein graft therapies that inhibit
CXCR4 may decrease neointimal hyperplasia without in-
creasing vein graft wall stress (by the Law of LaPlace).3,5,30
That the Cxcr4//Cxcr4/ vein grafts demon-
strated larger medial areas than other vein graft types was
surprising, in light of our previous finding that a large
proportion of vein graft medial cells derive from the bone
marrow.4 The higher prevalence of SMC-actin-positive
cells in the media of Cxcr4//Cxcr4/ vein grafts (Fig
5) suggested the possibility that Cxcr4//Cxcr4/ vein
grafts, compared with WT/WT vein grafts, comprised
more fibrocytes—bone marrow-derived cells that differen-
tiate from monocyte-like cells into SMC actin-expressing
myofibroblasts.21,31 However, the SMC actin-expressing
cells of the Cxcr4//Cxcr4/ vein grafts seemed rela-
tively deficient in two other key markers of fibrocytes21:
collagen I and CD45 (Figs 5 and 6). Consequently, we
infer that the media of Cxcr4//Cxcr4/ vein grafts is
populated principally by SMCs, and not bone marrow-
derived fibrocytes.
Reduction in CXCR4 activity reduced the prevalence
of leukocytes in arterialized vein grafts (Fig 6), just as
CXCR4 antagonism reduced macrophage density in in-
jured mouse femoral arteries.15 These observations accord
with models of CXCR4-dependent recruitment of inflam-
matory cells6 and may explain the reduction of vein graft
neointimal hyperplasia we observed in Cxcr4/ vein graft
recipients. By decreasing leukocyte density in arterializing
vein grafts, reduction of vein graft-extrinsic cells’ CXCR4
activity diminishes the number of cytokine-secreting cells in
the vein graft.18 A reduction in vein graft cytokine levels, in
turn, would be expected to reduce medial SMC activation,
manifest as proliferation and migration into the neointimal
layer of the vein graft.3 Perhaps for these reasons, our data
suggest that vein graft neointimal hyperplasia depends
upon CXCR4 activity in vein graft-extrinsic cells, rather
than vein graft-intrinsic cells, even though CXCR4 activa-
tion can drive SMC proliferation and migration.11
CXCR4 deficiency had no effect on vein graft re-
endothelialization, just as CXCR4 antagonism failed to
affect re-endothelialization of wire-injured arteries.14,15
This result may be attributable to one or more of several
factors. First, graft-extrinsic endothelial cells constitute
only 10% of total vein graft endothelial cells in our
model,4 and consequently our approach may not have been
sensitive enough to discern CXCR4-dependent differences
in such a small fraction of the vein graft endothelial cells.
Second, CXCR4-mediated endothelial progenitor cell re-
cruitment27 may be offset by CXCR4-promoted endothe-
lial cell apoptosis and cytokine secretion,13 which by re-
cruiting inflammatory cells to the vein graft may further
promote endothelial cell apoptosis.19Study limitations. These mouse studies were per-
ormed with interposition vein grafts and thus cannot
odel all of the hemodynamic parameters that are obtained
n vein grafts used to bypass partially patent, atherosclerotic
essels. In addition, our genetic approach to reducing
XCR4 activity, heterozygous gene deletion, cannot be
pplied to humans. However, the CXCR4 antagonist
lerixafor (AMD3100) is safely used in humans32,33 and
ould conceivably be used to treat vein grafts focally, at the
ime of implantation. Because our experiments did not use
lerixafor, our work cannot determine whether vein graft-
ocalized plerixafor treatment, perhaps in the form of a
eri-adventitial gel,34,35 could reduce vein graft neointimal
yperplasia by inhibiting CXCR4 not only on vein graft-
ntrinsic cells but also on graft-extrinsic cells, as they en-
eavor to migrate into the graft.34,35 Thus, the clinical
ranslatability of our CXCR4 findings remains to be deter-
ined.
ONCLUSIONS
The present study demonstrates that the SDF-1/
XCR4 signaling system in vein graft-extrinsic cells con-
ributes to vein graft neointimal hyperplasia. Mechanisms
nderlying this phenomenon include CXCR4-mediated
ecruitment of inflammatory cells to the vein graft.
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